Phase I/Iia, First-In-Human (FIH), Open-Label, Dose Escalation Trial With Expansion Cohorts To Evaluate Safety And Preliminary Efficacy Of CLDN6 CAR-T +/- CLDN6 RNA-LPX In Patients With CLDN6-Positive Relapsed Or Refractory Advanced Solid Tumors